Publications 2004

  1. Kowalska, T.; Kowalski, P.; Bojarski, A. J.; Duszyńska, B. Studies on the syntheses of 1-substituted benzimidazole derivatives. Acta Pol. Pharm. -Drug Res. 2004, 61, 361-366 (http://www.ncbi.nlm.nih.gov/pubmed/15747692).
  2. Paluchowska, M. H.; Charakchieva-Minol, S.; Tatarczynska, E.; Klodzinska, A.; Stachowicz, K.; Chojnacka-Wojcik, E. New 4-[ω-(diarylmethylamino)alkyl]- and 4-[ω-(diarylmethoxy)alkyl]-1-arylpiperazines as selective 5-HT1A/5-HT2A receptor ligands with differentiated in vivo activity. Pol. J. Pharmacol. 2004, 56, 743-754 (http://www.ncbi.nlm.nih.gov/pubmed/15662087).
  3. Kossakowski, J.; Raszkiewicz, A.; Bugno, R.; Bojarski, A. J. Introduction of a new complex imide system into the structure of LCAPs. The synthesis and a 5-HT1A, 5-HT2A and D2 receptor binding study. Pol. J. Pharmacol. 2004, 56, 843-848 (http://www.ncbi.nlm.nih.gov/pubmed/15662099).
  4. Wasylewski, M. Evaluation of riboflavin binding protein domain interaction using differential scanning calorimetry . Biochim. Biophys. Acta 2004, 1702, 137-143 (http://www.ncbi.nlm.nih.gov/pubmed/15488765).
  5. Bojarski, A. J.; Duszyńska, B.; Kołaczkowski, M.; Kowalski, P.; Kowalska, T. The impact of spacer structure on 5-HT7 and 5-HT1A receptor affinity in the group of long-chain arylpiperazine ligands. Bioorg. Med. Chem. Lett. 2004, 14, 5863-5866 (http://www.ncbi.nlm.nih.gov/pubmed/15501057).
  6. Zajdel, P.; Subra, G.; Bojarski, A. J.; Duszyńska, B.; Pawłowski, M.; Martinez, J. A new class of arylpiperazine derivatives: the library synthesis on SynPhase lanterns and biological evaluation on serotonin 5-HT1A and 5-HT2A receptors. J. Comb. Chem. 2004, 6, 761-767 (http://www.ncbi.nlm.nih.gov/pubmed/15360211).
  7. Jurczyk, S.; Kołaczkowski, M.; Maryniak, E.; Zajdel, P.; Pawłowski, M.; Tatarczyńska, E.; Kłodzinska, A.; Chojnacka-Wojcik, E.; Bojarski, A. J.; Charakchieva-Minol, S.; Duszyńska, B.; Nowak, G.; Maciąg, D. New arylpiperazine 5-HT1A receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation. J. Med. Chem. 2004, 47, 2659-2666 (http://www.ncbi.nlm.nih.gov/pubmed/15115407).
  8. Lorenc-Koci, E.; Wojcikowski, J.; Kot, M.; Haduch, A.; Boksa, J.; Daniel, W. A. Disposition of 1,2,3,4,-tetrahydroisoquinoline in the brain of male Wistar and Dark Agouti rats. Brain Res. 2004, 996, 168-179 (http://www.ncbi.nlm.nih.gov/pubmed/14697494).
  9. Antkiewicz-Michaluk, L.; Wardas, J.; Michaluk, J.; Romańska, I.; Bojarski, A.; Vetulani, J. Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int. J. Neuropsychopharmacol. 2004, 7, 155-163 (http://www.ncbi.nlm.nih.gov/pubmed/14741061).
  10. Zajdel, P.; Bojarski, A. J.; Bugno, R.; Jurczyk, S.; Kołaczkowski, M.; Nowak, M.; Subra, G.; Martinez, J.; Pawłowski, M. A study on application of impregnated synthetic peptide TLC stationary phases for the screening of 5-HT1A ligands. Part 2. Biomed. Chromatogr. 2004, 18, 542-549 (http://www.ncbi.nlm.nih.gov/pubmed/15386518).
  11. Bojarski, A. J.; Mokrosz, M. J.; Duszyńska, B.; Kozioł, A.; Bugno, R. New Imide 5-HT1A Receptor Ligands Modification of Terminal Fragment Geometry. Molecules 2004, 3, 170-177 (http://www.ncbi.nlm.nih.gov/pubmed/18007421).